Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.68 |
| ▸ | GRM6 | O15303 | 1/20 | 0.68 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.68 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.68 |
| ▸ | GSR | P00390 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.68 |
| ▸ | GRM5 | P41594 | 1/20 | 0.68 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.68 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.68 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.68 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.68 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.68 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.68 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.68 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.68 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.68 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.68 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.68 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022755 | 1.00 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL93831 | 1.00 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL29438088 | 1.00 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL30571083 | 1.00 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL93830 | 1.00 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Bromide SCHEMBL31300189 | 0.97 | GRM8 (0.65) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Hydrochloric Acid SCHEMBL18173930 | 0.97 | GRM8 (0.65) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL10361106 | 0.97 | GRM8 (0.65) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Hydrochloric Acid SCHEMBL2251424 | 0.97 | GRM8 (0.65) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Water SCHEMBL2288176 | 0.97 | GRM8 (0.65) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378328-B2 | Biohybrid peptidoglycan oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-08-05 | — | — | US | claimed |
| US-20240041798-A1 | OVARIAN CANCER VACCINES | THE CLEVELAND CLINIC FOUNDATION | 2024-02-08 | — | — | US | claimed |
| CN-117466978-A | Muramyl dipeptide structure modification and reconstruction method and application thereof in lipid nanoparticle and nucleic acid drug delivery | 中国药科大学 | 2024-01-30 | — | — | CN | claimed |
| US-11786489-B2 | Ovarian cancer vaccines | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-10-17 | — | — | US | claimed |
| CN-112805305-B | Biohybrid peptidoglycan oligomers | 南洋理工大学 | 2023-03-21 | — | — | CN | claimed |
| US-20220213232-A1 | BIOHYBRID PEPTIDOGLYCAN OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-07-07 | — | — | US | claimed |
| US-11090284-B2 | Ovarian cancer vaccines | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-08-17 | — | — | US | claimed |
| US-20110002983-A1 | COMPOUND | IMUTHES LIMITED (GB) | 2011-01-06 | — | — | US | claimed |
| EP-4417216-B1 | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS RLP2086 ANTIGENS | WYETH LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12492222-B2 | Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity | NUTRIVERT INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250359575-A1 | METHOD FOR IMPROVING FLAVOR OF FOOD | AJINOMOTO CO., INC. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4642479-A1 | MODIFIED BCG VACCINE | University of the Witwatersrand, Johannesburg (ZA) | 2025-11-05 | — | — | EP | disclosed |
| US-20250268839-A1 | PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-08-28 | — | — | US | disclosed |
| US-12378328-B2 | Biohybrid peptidoglycan oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-08-05 | — | — | US | disclosed |
| CN-1512890-A | HCG formulation | 开米卡公司 | 2004-07-14 | — | — | CN | disclosed |
| EP-1131354-A4 | CONTRACEPTIVE ANTIBODY VACCINES | EURO CELTIQUE SA (LU) | 2003-01-02 | — | — | EP | disclosed |
| EP-1218499-A2 | RESCUE OF MUMPS VIRUS FROM cDNA | Wyeth (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1131354-A1 | CONTRACEPTIVE ANTIBODY VACCINES | Euro-Celtique, S.A. (LU) | 2001-09-12 | — | — | EP | disclosed |
| WO-2001009309-A2 | RESCUE OF MUMPS VIRUS FROM cDNA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000029443-A1 | CONTRACEPTIVE ANTIBODY VACCINES | EURO-CELTIQUE, S.A. (LU) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378328-B2 | Biohybrid peptidoglycan oligomers | NOD2, DDOST, CD14 | GRM8 2869/4885GRM6 3101/4885GRIN2D 4129/4885 |
| US-20220213232-A1 | BIOHYBRID PEPTIDOGLYCAN OLIGOMERS | NOD2, DDOST, CD14 | GRM8 2869/4885GRM6 3101/4885GRIN2D 4129/4885 |
| US-20110002983-A1 | COMPOUND | C5AR1, C5AR2, ARG1 | GRM8 1896/4885GRM6 1282/4885GRIN2D 3925/4885 |
| US-12492222-B2 | Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity | MIF, DNPEP, GLMN | GRM8 1607/4885GRM6 890/4885GRIN2D 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.